Our Facilities
will remain open & operational during the COVID-19 pandemic

 

436
Clinical Trials
3
Commercial Products
300,000+
Shipments
100+
Countries

The Latest From Our Blog View All

Coronavirus Update: Actions We're Taking

Cryoport continues to proactively monitor the global spread of the COVID-19 virus and to take appropriate mitigating actions. Our team is committed to the health and safety of our employees, clients, patients and suppliers.

We expect all of our facilities to remain open during the COVID-19 pandemic as Cryoport provides vital supporting services to our global Healthcare Delivery, Public Health and Transportation Systems Sectors, which are identified as “Essential Critical Infrastructure Workers During COVID-19.

It is our plan that our Global Logistics Center Network, along with all operating and support departments, will continue to conduct business as usual.  With the planning and actions we have taken, we intend to continue supporting your temperature-controlled logistics needs.

If you have any questions or concerns, please call your Cryoport contact or our general number at +1 (949) 470 - 2300. For a quick response, please email info@cryoport.com.

Cryoport Systems, Inc.
Cryoport-NewTagline-Print PNG-1


PREVIOUS UPDATES LISTED BELOW

Thu, March 12, 2020

Cryoport is actively monitoring the spread of COVID-19 globally and proactively working with its global partners to minimize its impact on the supply chain. Cryoport has implemented an all-inclusive business continuity program that focuses on measuring the risk of disruptions and minimizing any impact to our and our clients’ global operations.

New FDA Guidelines on Gene Therapy IND Process A Significant Step Forward

Recently the FDA’s Center for Biologics Evaluation and Research issued its guidance to the regenerative medicine industry on best practices for submitting an IND application to the FDA for gene therapies. The document provides valuable guidance on key aspects of the IND process and the potential pitfalls for errors or key omissions, but it has left key logistics aspects vague as the regenerative therapy industry works in parallel to develop best practices.